{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for angiotensin root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2011)
Source URL:
First approved in 1988
Source:
ANDA089673
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA078003
(1989)
Source URL:
First approved in 1988
Source:
21 CFR 333A
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
BLA125296
(2011)
Source URL:
First approved in 1986
Source:
ANDA070994
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA019258
(1986)
Source URL:
First approved in 1986
Source:
NDA019258
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2013)
Source URL:
First approved in 1985
Source:
NDA021535
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT00790140: Phase 4 Interventional Unknown status Esophageal Cancer
(2005)
Source URL:
First approved in 1984
Source:
NeuroBion by BENARD INDUSTRIES INC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 1984
Source:
Hemocyte F by US Pharmaceutical Corporation
Source URL:
Class:
POLYMER
Hypromellose is a semisynthetic, inert, viscoelastic methyl and hydroxypropyl mixed ether of cellulose used as eye drops, as well as an excipient and controlled-delivery component in oral medicaments, found in a variety of commercial products. Hypromellose is considered an inert substance as it has no direct pharmacological activity. The viscosity promoting properties of hypromellose prolong the retention time and improve adhesion of synthetic tears to the cornea and conjunctiva. As a result, the tear film breakdown time is prolonged and/or the tear film stability is enhanced. A stable tear film protects the cornea from dryness Hypromellose is the most commonly used in hydrophilic matrix fabrication. Hypromellose provides the release of a drug in a controlled manner, effectively increasing the duration of release of a drug to prolong its therapeutic effect.
Status:
Possibly Marketed Outside US
Source:
ANDA070098
(1984)
Source URL:
First approved in 1984
Source:
ANDA070098
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
FLUIDBASE AHA 10 by LABORATORIO GENOVE S.A.
(2016)
Source URL:
First approved in 1983
Source:
NDA018861
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA062124
(1982)
Source URL:
First approved in 1982
Source:
ANDA062124
Source URL:
Class:
POLYMER
